cilengitide has been researched along with Carcinoma, Non-Small Cell Lung in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jeong, J; Kim, J | 1 |
| Aziza, R; Bigay-Gamé, L; Chatelut, E; Cohen-Jonathan Moyal, E; Delord, JP; Dierickx, L; Filleron, T; Gomez-Roca, C; Khalifa, J; Massabeau, C; Mazières, J; Modesto, A; Mounier, M; Olivier, P; Plat, G; Rouquette, I; Toulas, C | 1 |
| Atanackovic, D; Barlesi, F; Bennouna, J; Feurer, M; Germonpre, P; Goekkurt, E; Gridelli, C; Hicking, C; Krzakowski, M; Lena, H; Milanowski, J; O'Byrne, K; Picard, M; Schuette, W; Straub, J; Szczesna, A; Vansteenkiste, J; Verhoeven, D; Waller, CF | 1 |
| Cardenal, F; Eckmayr, J; Kerber, A; Manegold, C; Schuette, W; Ulsperger, E; Vansteenkiste, J; von Pawel, J; Woll, PJ | 1 |
| Albert, JM; Cao, C; Geng, L; Hallahan, DE; Leavitt, L; Lu, B | 1 |
3 trial(s) available for cilengitide and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Continuous Infusion of Cilengitide Plus Chemoradiotherapy for Patients With Stage III Non-Small-cell Lung Cancer: A Phase I Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Positron Emission Tomography Computed Tomography; Receptors, Vitronectin; Snake Venoms; Vinorelbine | 2018 |
Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Female; Gemcitabine; Humans; Integrin alphaVbeta3; Lung Neoplasms; Male; Middle Aged; Prognosis; Proportional Hazards Models; Receptors, Vitronectin; Snake Venoms; Treatment Outcome; Vinblastine; Vinorelbine | 2015 |
Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Female; Humans; Integrins; Lung Neoplasms; Male; Middle Aged; Snake Venoms; Taxoids | 2013 |
2 other study(ies) available for cilengitide and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Combination Effect of Cilengitide with Erlotinib on TGF-β1-Induced Epithelial-to-Mesenchymal Transition in Human Non-Small Cell Lung Cancer Cells.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Epithelial-Mesenchymal Transition; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Snake Venoms; Transforming Growth Factor beta1 | 2022 |
Integrin alpha v beta 3 antagonist Cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Combined Modality Therapy; Endothelial Cells; Endothelium, Vascular; Humans; Integrin alphaVbeta3; Lung Neoplasms; Radiation Tolerance; Snake Venoms | 2006 |